8-allyl-4-(benzyloxy)-7-hydroxycoumarin | 69076-27-3

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 香豆素及其衍生物
• 英文名称: 8-allyl-4-(benzyloxy)-7-hydroxycoumarin
• 英文别名: 8-Allyl-4-benzyloxy-7-hydroxycoumarin；7-hydroxy-4-phenylmethoxy-8-prop-2-enylchromen-2-one
• CAS: 69076-27-3
• 化学式: C₁₉H₁₆O₄
• 分子量: 308.334
• InChiKey: AIJSTGONGVTIFH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  23
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  55.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  8-allyl-4-(benzyloxy)-7-hydroxycoumarin 在 palladium on activated charcoal 氢氧化钾 、 氢气 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 4.0h， 生成 1-(4-chlorobenzyl)-4-[2-hydroxy-3-(4-hydroxy-8-n-propylcoumarin-7-yloxy)propyl]piperazine
  参考文献：
  名称：

  N-Benzylpiperazino derivatives of 3-nitro-4-hydroxycoumarin with H1 antihistamine and mast cell stabilizing properties

  摘要：

  In a small range finding study a number of N-benzylpiperazino derivates of 3-nitro-4-hydroxycoumarin have been shown to combine potent H1-antihistamine activity with that of mast cell stabilization as demonstrated by their activity as antagonists of histamine on guinea pig ileum and by their inhibition of the release of histamine in rat passive peritoneal anaphylaxis (PPA). The most potent compound, 1-[2-hydroxy-3-[(4-hydroxy-3-nitrocoumarin-7-yl)oxy]propyl]-4- (4-chlorobenzyl)piperazine, 30, had a pA2 of 9.0 against histamine on guinea pig ileum and inhibited histamine release in the rat PPA test with a potency similar to that of disodium cromoglycate.

  DOI：

  10.1021/jm00377a013

文献信息

• Heterocyclic coumarin derivatives
  申请人：Beecham Group Limited

  公开号：US04263299A1

  公开（公告）日：1981-04-21

  A compound of formula (I): ##STR1## and pharmaceutically acceptable salts thereof, wherein R is hydrogen or an alkyl group containing up to 6 carbon atoms; X is a bond or oxygen; Y is --(CH.sub.2).sub.n -- where n is 0 or an integer from 1 to 5 wherein one carbon atom not bound to the nitrogen atom may be optionally substituted with a hydroxy group; and Z is hydrogen or halogen; may be used in the prophylaxis and treatment of diseases whose symptoms are controlled by the mediators of the allergic response, for example asthma, hay-fever, rhinitis and allergic eczema.

  化合物的结构式（I）：##STR1##及其药学上可接受的盐，其中R是氢或含有最多6个碳原子的烷基基团；X是键或氧；Y是--(CH.sub.2).sub.n--，其中n为0或1至5的整数，其中一个未与氮原子结合的碳原子可以选择性地被羟基取代；Z是氢或卤素；可用于预防和治疗由过敏反应介质控制症状的疾病，例如哮喘、花粉症、鼻炎和过敏性湿疹。
• Heterocyclic coumarin derivatives, their preparation and pharmaceutical compositions comprising said derivatives
  申请人：BEECHAM GROUP PLC

  公开号：EP0010392A1

  公开（公告）日：1980-04-30

  A compound of formula (I): and pharmaceutically acceptable salts thereof, wherein R is hydrogen or an alkyl group containing up to 6 carbon atoms; X is a bond or oxygen; Y is -(CH2)n -where n is 0 or an integer from 1 to 5 wherein one carbon atom not bound to the nitrogen atom may be optionally substituted with a hydroxy group; and Z is hydrogen or halogen; e.g. 1-(4-chlorobenzyl) -4-[3-(4-hydroxy-3-nitro- coumarin-7-yloxy) propyl] piperazine; may be used in the prophylaxis and treatment of diseases whose symptoms are controlled by the mediators of the allergic response, for example asthma, hay-fever, rhinitis and allergic eczema. A compound of formula (I) is prepared by reacting a compound of formula (II) or a salt thereof wherein R, X, Y, and Z are defined with respect to formula (i) with a nitrating agent

  式(I)化合物 及其药学上可接受的盐类，其中 R 是氢或最多含有 6 个碳原子的烷基；X 是键或氧；Y 是-(CH2)n -其中 n 是 0 或 1 至 5 的整数，其中未与氮原子结合的一个碳原子可任选被羟基取代；Z 是氢或卤素；例如：1-(4-氯苄基)-4-[3-(4-羟基-3-硝基香豆素-7-氧基)丙基]哌啶。g. 1-(4-氯苄基)-4-[3-(4-羟基-3-硝基香豆素-7-氧基)丙基]哌嗪；可用于预防和治疗其症状受过敏反应介质控制的疾病，例如哮喘、花粉症、鼻炎和过敏性湿疹。 式（I）化合物是通过式（II）化合物或其盐反应制备的 其中 R、X、Y 和 Z 的定义见式 (i)。
• Coumarin intermediates
  申请人：BEECHAM GROUP PLC

  公开号：EP0050396A1

  公开（公告）日：1982-04-28

  Compounds of the formula (II): or a salt thereof, wherein R is hydrogen or an alkyl group containing up to 6 carbon atoms; X is a covalent bond or oxygen; Y is -(CH2)n- where n is 0 or an integer from 1 to 5 wherein one carbon atom not bound to the nitrogen atom may be optionally substituted with a hydroxy group; and Z is hydrogen or halogen are useful intermediates in the preparation of pharmacologically active compounds described in European Patent Application No 79302141.

  式 (II) 的化合物：或其盐，其中 R 是氢或最多含有 6 个碳原子的烷基；X 是共价键或氧；Y 是-(CH2)n-，其中 n 是 0 或 1 至 5 的整数，其中未与氮原子结合的一个碳原子可任选被羟基取代；Z 是氢或卤素，是制备欧洲专利申请第 79302141 号所述药理活性化合物的有用中间体。
• BUCKLE, D. R.;OUTRED, D. J.;SMITH, H.;SPICER, B. A., J. MED. CHEM., 1984, 27, N 11, 1452-1457
  作者：BUCKLE, D. R.、OUTRED, D. J.、SMITH, H.、SPICER, B. A.

  DOI：——

  日期：——
• US4263299A
  申请人：——

  公开号：US4263299A

  公开（公告）日：1981-04-21